OTC Markets OTCPK • USD Halberd Corporation (HALB) Follow Compare 0.0043 +0.0006 +(16.22%) At close: January 10 at 1:43:45 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Halberd Update on WatchDawg® PTSD Treatment Next Phase Pilot StudyJACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting i Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring SystemJACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wo Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD Contributing Funding and a Significant Additional Tool to Combat PTSD and TBIJACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology and At Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction Early Pilot Study Data from Veteran Volunteers is Compelling - Part BJACKSON CENTER, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also growing qui Halberd Corp. Issues Letter to Shareholders JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to it shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-axTM TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing concern on how Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-Ax™ nasa Halberd/Athena GTX Research Promises a Much Brighter Future Walt Disney once said, "All our dreams can come true if we have the courage to pursue them". JACKSON CENTER, PA / ACCESSWIRE / May 22, 2024 / Halberd Corporation (OTC PINK:HALB) in cooperation with Athena GTX, Inc is standing at the threshold of some ... Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the ... Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited ... Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd ... Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and ... Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast" JACKSON CENTER, PA / ACCESSWIRE / February 6, 2024 / Halberd Corporation's (OTC PINK:HALB) and Athena GTX's executives interviewed on "The Street Reports," discuss the relationship between Halberd and Athena and why that relationship is going to advance ... Performance Overview Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return HALB S&P 500 YTD +7.50% -1.35% 1-Year -57.00% +22.51% 3-Year -80.45% +24.59%